Impax Laboratories (IPXL) Receiving Favorable Media Coverage, Report Finds

News headlines about Impax Laboratories (NASDAQ:IPXL) have trended positive on Saturday, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Impax Laboratories earned a news impact score of 0.28 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 50.7385352274593 out of 100, meaning that recent press coverage is somewhat likely to have an impact on the stock’s share price in the next few days.

These are some of the headlines that may have effected Accern’s scoring:

Impax Laboratories (NASDAQ:IPXL) traded down $0.25 on Friday, hitting $16.65. The company had a trading volume of 843,921 shares, compared to its average volume of 930,777. The firm has a market cap of $1,252.52, a PE ratio of -2.66, a P/E/G ratio of 1.07 and a beta of 0.94. The company has a current ratio of 1.81, a quick ratio of 1.32 and a debt-to-equity ratio of 1.59. Impax Laboratories has a 1-year low of $7.75 and a 1-year high of $25.70.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. The firm had revenue of $206.40 million for the quarter, compared to analysts’ expectations of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. Impax Laboratories’s quarterly revenue was down 9.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.37 EPS. equities analysts expect that Impax Laboratories will post 0.63 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on IPXL. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the stock a “hold” rating in a research note on Monday, December 18th. Cantor Fitzgerald set a $35.00 target price on Impax Laboratories and gave the stock a “buy” rating in a research note on Friday, December 15th. Guggenheim began coverage on Impax Laboratories in a research note on Tuesday, December 12th. They set a “neutral” rating and a $18.00 target price for the company. Cowen reissued a “hold” rating and set a $16.00 target price on shares of Impax Laboratories in a research note on Friday, November 10th. Finally, UBS Group upped their price target on Impax Laboratories from $12.00 to $16.00 and gave the stock a “sell” rating in a report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.47.

TRADEMARK VIOLATION NOTICE: “Impax Laboratories (IPXL) Receiving Favorable Media Coverage, Report Finds” was published by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with's FREE daily email newsletter.

Leave a Reply